T
HELP

Tidemark’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Tidemark’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$866 Hold
131
– – ﹤0.01% 754
2026
Q1 		$629 Hold
131
– – ﹤0.01% 737
2025
Q4 		$1.07K Hold
131
– – ﹤0.01% 605
2025
Q3 		$772 Hold
131
– – ﹤0.01% 645
2025
Q2 		$1.1K Hold
131
– – ﹤0.01% 639
2025
Q1 		$831 Buy
+131
New +$1.13K ﹤0.01% 655

Other funds holding HELP

VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Sio Capital Management
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Tidemark's HELP Position: Q2 2026 in Review

Tidemark held its Helus Pharma Inc. Common Stock (HELP) position steady in Q2 2026 at 131 shares worth $866. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Tidemark first reported a position in HELP in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.1K in Q2 2025. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • Tidemark held 131 shares of Helus Pharma Inc. Common Stock worth $866 as of Q2 2026.
  • Tidemark left its Helus Pharma Inc. Common Stock share count unchanged in Q2 2026.
  • Helus Pharma Inc. Common Stock made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #754 holding.
  • Tidemark first reported a position in Helus Pharma Inc. Common Stock in Q1 2025 and has held it in 6 quarters since.
  • Tidemark's Helus Pharma Inc. Common Stock position peaked at $1.1K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.